CagriSema’s latest women’s health results raise a useful question: does reproductive life stage change how much weight people lose? The new analysis offers clues, but it cannot establish that menopause itself changes the treatment response. Its headline 25% average weight loss also describes an idealized continued-treatment scenario, rather than the outcome every woman should expect.
On October 20, Novo Nordisk reported two exploratory analyses of REDEFINE 1 presented at The Menopause Society’s 2026 annual meeting. These are new looks at an existing trial, not a newly completed menopause-specific trial. The distinction matters for interpreting both the encouraging findings and their limits.
What the 25% figure actually measures
The sponsor’s analysis included the 2,309 women enrolled across REDEFINE 1’s four treatment groups. At 68 weeks, estimated average weight loss was 25.0% with CagriSema and 3.0% with placebo, using the efficacy estimand. That estimates what would happen if participants continued their assigned treatment and used no other weight-loss therapies. It is neither a guarantee nor simply an average of successful completers.
The original randomized trial report describes 3,417 adults without diabetes who had obesity, or overweight with at least one obesity-related complication. All groups received lifestyle intervention. The research regimen combined once-weekly injected cagrilintide and semaglutide, with a target of 2.4 mg of each. Dose adjustments were permitted; these details describe the experiment, not instructions for treatment. Our CagriSema profile explains the investigational combination.
For the whole trial population, the original paper reported 20.4% average weight loss with the combination under the treatment-policy estimand, which includes the effects of treatment discontinuation or rescue intervention. Comparing that figure directly with the new women-only 25.0% mixes both population and analysis method. It cannot measure an extra benefit from being female. The estimand guide explains why these questions produce different numbers.
Menopause groups were reconstructed afterward
A second analysis considered 1,902 women assigned to CagriSema or placebo. The sponsor’s subgroup table reports efficacy-estimand weight reductions of 26.7% versus 2.1% before menopause, 24.8% versus 1.7% around menopause, and 23.1% versus 2.6% after menopause. These are comparisons with placebo within each reported category, all at week 68.
However, reproductive stage was not prospectively measured using a dedicated staging assessment or biochemical confirmation. Investigators assigned categories afterward using age, recorded symptoms and medical history. Women using hormone therapy were assessed separately, regardless of age or menopausal status. The three stage-specific rows therefore should not be mistaken for a complete breakdown of every woman in the analysis.
This approach makes use of available data, but age-based categories can misclassify reproductive stage. The groups also differ in age by design. Their numerical differences cannot isolate a hormonal explanation from other characteristics associated with aging. Nor do these results establish that hormone therapy improves or weakens CagriSema’s effect.
A positive result within each group does not prove a difference between groups
Novo reports statistically significant comparisons with placebo, while stating that the subgroup P values were not adjusted for multiple testing. It also says no formal treatment-by-subgroup interaction test was performed. Such a test would address whether treatment effects differ across the groups; separate positive comparisons with placebo do not answer that question.
The women’s analysis likewise did not include formal treatment-by-sex interaction testing. Calling CagriSema especially effective for women, or ranking its effects across menopause stages as established facts, would go beyond the reported evidence. The useful signal is that substantial reductions were estimated in each reported stage, supporting further study with reproductive status measured more carefully. Our trial-reading guide offers a framework for assessing subgroup headlines.
Waist measurements and safety need their own context
Among women overall, the sponsor reports an estimated waist-circumference reduction of 20.5 cm with CagriSema versus 4.7 cm with placebo under the efficacy estimand. The REDEFINE 1 registry identifies waist circumference as a secondary endpoint. A smaller waist is an anthropometric finding; it does not directly quantify visceral fat or establish fewer heart attacks in this subgroup.
Safety figures in the announcement come from the overall trial, not a menopause-specific safety comparison. The original paper reports gastrointestinal adverse events in 79.6% of combination recipients versus 39.9% with placebo, mostly transient and mild to moderate. Adverse events led to discontinuation in 5.9% versus 3.5%. These findings belong beside the weight results and cannot establish identical tolerability at every reproductive stage.
What would make the next update more informative?
The sponsor’s October 20 release states that CagriSema remains unapproved in the United States. An application and a conference presentation are separate from a regulatory decision; the regulatory watch explains that boundary. This analysis does not create a menopause indication or justify changing an existing medicine.
More informative follow-up would include complete subgroup methods, uncertainty intervals, formal interaction analyses and prospectively collected reproductive staging. For a care discussion, the immediate question is whether evidence matches the person’s health conditions and approved treatment options—not which subgroup has the largest percentage. Readers should also know the source boundary here: the original trial paper and registry were inspected, but the new subgroup findings are drawn from Novo’s announcement. The conference posters and separate trial supplement were not reviewed.



